Literature DB >> 7867870

Influence of dietary composition on the inhibition of fat absorption by orlistat.

C Güzelhan1, J Odink, J J Niestijl Jansen-Zuidema, D Hartmann.   

Abstract

Orlistat, a potent and selective inhibitor of gastrointestinal lipases, is designed for the treatment of obesity. The effect of orlistat on dietary fat absorption, when it was administered with diets differing in fibre content (high and low) and accessibility of fat (intra- and extracellular fat), was investigated in 32 hospitalized healthy males, according to an open, two-factorial study design. The subjects were randomly allocated to one of four parallel groups of equal size: A = intracellular fat, high fibre (28 g/day); B = extracellular fat, high fibre; C = extracellular fat, low fibre (9 g/day); or D = intracellular fat, low fibre. After a 5-day run-in period to accustom the volunteers to the standardized diet (2500 kcal and 84 g fat per day) and to establish baseline faecal fat parameters, they received 80 mg orlistat, three times daily mid-way through each meal for 8 days. Faeces were collected to measure total fat and free fatty acid excretions. The mean baseline-corrected excretion (% of dietary fat) in groups A, B, C and D, respectively, was 37.0, 30.4, 30.3 and 34.5 for total fat, and 6.5, 4.3, 2.6 and 3.9 for free fatty acids. The 95% confidence intervals for the difference between the means for high fibre and low fibre groups and for intracellular fat and extracellular fat groups, respectively, were 1.4 +/- 4.9 and 5.5 +/- 4.9 for total fat, and 2.2 +/- 3.1 and 1.9 +/- 3.1 for free fatty acids. The statistically significant difference (P < 0.05) in total faecal fat between intracellular fat and extracellular fat groups, in absolute terms < 5 g fat/day, was not regarded as clinically relevant. Under the conditions of this study, dietary fibre content and accessibility of fat had no relevant effect on the inhibition of fat absorption by orlistat.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7867870     DOI: 10.1177/030006059402200502

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  3 in total

Review 1.  Orlistat: a review of its use in the management of obesity.

Authors:  K M Hvizdos; A Markham
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

Review 2.  Orlistat.

Authors:  W McNeely; P Benfield
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

3.  Supplementation with dairy calcium and/or flaxseed fibers in conjunction with orlistat augments fecal fat excretion without altering ratings of gastrointestinal comfort.

Authors:  Mette Kristensen; Signe Rømer Juul; Karina Vejrum Sørensen; Janne Kunchel Lorenzen; Arne Astrup
Journal:  Nutr Metab (Lond)       Date:  2017-02-07       Impact factor: 4.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.